News

Public · Published

Argus Research maintains Amgen at Buy, raises price target to $515 from $460

Argus Research kept its Buy rating on Amgen and raised its price target to $515 from $460. The new target is a 12.0% increase and implies 10.0% upside from Amgen's Nov. 11 closing price of $468.11.

Published:

Updated:

What happened

Argus Research kept its Buy rating on Amgen and raised its price target to $515 from $460. The new target is a 12.0% increase and implies 10.0% upside from Amgen’s Nov. 11 closing price of $468.11.

Confirmed

Global impact / market context

The higher target signals that Argus sees more potential value in Amgen shares, but it is an analyst view, not a company forecast or guaranteed return. If investors act on it, buying could support the share price; the article does not report a market reaction.

Analyst inference

Recent analyst views are mixed: five notes from the past 30 days set targets between $435 and $530, with ratings ranging from Hold to Buy. That spread shows differing expectations and places Argus’s $515 target near the upper end.

Confirmed

What to watch

  1. Compare future analyst ratings and targets with Argus’s $515 figure; changes in the range of views could alter investor expectations for Amgen shares. Analyst inference
  2. Watch whether Amgen’s share price moves toward or away from the target’s implied 10.0% upside from the Nov. 11 close; no response is reported here. Analyst inference
  3. The article gives no reason for Argus’s higher target, so any later explanation linking it to Amgen’s revenue, costs, or business outlook would be new information. Analyst inference

Evidence

  • Original source link unavailable